Cormedix (CRMD) closed at $4.50 on November 18, 2026, down 3.6% from the previous close, on volume of 1,456,184 shares (30-day average 1,781,462).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Diagonal Put Spread | 18-Dec-26 : 21-Jan-289 : 8 P | 500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision (NASDAQ: PYPD)
TipRanks (Mon, 16-Nov 9:10 AM ET)
CorMedix Earnings Call Highlights Heron Deal and DefenCath Outlook
TipRanks (Sun, 15-Nov 12:11 AM ET)
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Fri, 6-Nov 8:30 AM ET)
Market Chameleon (Mon, 2-Nov 2:56 AM ET)
Globe Newswire (Mon, 2-Nov 7:30 AM ET)
Globe Newswire (Mon, 19-Oct 7:30 AM ET)
PRNewswire (Thu, 15-Oct 7:30 AM ET)
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Cormedix trades on the NASDAQ stock market under the symbol CRMD.
As of November 18, 2026, CRMD stock price declined to $4.50 with 1,456,184 million shares trading.
CRMD has a beta of 0.69, meaning it tends to be less sensitive to market movements. CRMD has a correlation of 0.01 to the broad based SPY ETF.
CRMD has a market cap of $357.65 million. This is considered a Small Cap stock.
Last quarter Cormedix reported $55 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.08.
In the last 3 years, CRMD traded as high as $17.43 and as low as $2.89.
The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, AVUV, IWM, VXF, XPH.
CRMD has underperformed the market in the last year with a price return of -54.9% while the SPY ETF gained +10.8%. CRMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.3% and -19.1%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
CRMD support price is $4.47 and resistance is $4.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.